Kobayashi Intetsu, Murakami Kazunari, Kato Mototsugu, Kato Seiichi, Azuma Takeshi, Takahashi Shin'ichi, Uemura Naomi, Katsuyama Tsutomu, Fukuda Yoshihiro, Haruma Ken, Nasu Masaru, Fujioka Toshio
Chemotherapy Division, Mitsubishi Chemical Medience Corporation, Tokyo, Japan.
J Clin Microbiol. 2007 Dec;45(12):4006-10. doi: 10.1128/JCM.00740-07. Epub 2007 Oct 17.
Surveillance of Helicobacter pylori antimicrobial susceptibility reflecting the general population in Japan is limited. The antimicrobial susceptibilities of 3,707 H. pylori strains isolated from gastric mucosa samples of previously untreated patients diagnosed with gastroduodenal diseases at 36 medical facilities located throughout Japan between October 2002 and September 2005 were evaluated. Using an agar dilution method for antimicrobial susceptibility testing of H. pylori, the MIC distributions and trends during the study period for clarithromycin, amoxicillin, and metronidazole were studied. While the MIC(50) and MIC(90) for clarithromycin did not change during the 3-year period, the MIC(80) showed a 128-fold increase. Furthermore, the rate of resistance increased yearly from 18.9% (2002 to 2003) to 21.1% (2003 to 2004) and 27.7% (2004 to 2005). With a resistance rate of 19.2% among males compared to 27.0% among females, a significant gender difference was observed (P < 0.0001). Our study shows that in Japan, there is an evolving trend towards increased resistance to clarithromycin with geographical and gender differences as well as between clinical disease conditions. No significant changes in resistance were observed for amoxicillin and metronidazole during the period. While the benefit of H. pylori antimicrobial susceptibility testing has been debated in Japan, current empirical regimens are not based on susceptibility data representative of the general population. The development of an effective H. pylori eradication regimen in Japan will require continued resistance surveillance as well as a better understanding of the epidemiology of resistance.
在日本,反映普通人群情况的幽门螺杆菌抗菌药敏监测十分有限。对2002年10月至2005年9月期间从日本各地36家医疗机构诊断为胃十二指肠疾病的未经治疗患者的胃黏膜样本中分离出的3707株幽门螺杆菌菌株的抗菌药敏进行了评估。采用琼脂稀释法对幽门螺杆菌进行抗菌药敏试验,研究了克拉霉素、阿莫西林和甲硝唑在研究期间的MIC分布及变化趋势。虽然克拉霉素的MIC(50)和MIC(90)在3年期间没有变化,但MIC(80)增加了128倍。此外,耐药率从18.9%(2002年至2003年)逐年上升至21.1%(2003年至2004年)和27.7%(2004年至2005年)。男性耐药率为19.2%,女性为27.0%,存在显著性别差异(P<0.0001)。我们的研究表明,在日本,对克拉霉素的耐药性呈上升趋势,存在地域和性别差异以及临床疾病情况之间的差异。在此期间,阿莫西林和甲硝唑的耐药性没有显著变化。虽然幽门螺杆菌抗菌药敏试验的益处在日本一直存在争议,但目前的经验性治疗方案并非基于代表普通人群的药敏数据。在日本制定有效的幽门螺杆菌根除方案需要持续的耐药监测以及对耐药流行病学的更好理解。